BACKGROUND: Lung transplantation (LTx) is a therapeutic option for @entity1 with life-threatening @entity1030 ( @entity1030 ) that is refractory to conventional therapies. The survival benefit of LTx for @entity1030 is difficult to assess. The aim of this study was to evaluate the Swedish series of LTx performed to treat @entity1030 and to identify differences in outcome between @entity1030 related to severe @entity8693 ( @entity8693 ) and @entity1030 with normal alpha-1-antitrypsin (AAT) levels. METHODS: We retrospectively reviewed the data of 342 @entity1 (128 @entity8693 and 214 non- @entity8693 ) receiving lung transplants for end stage @entity1030 from 1990 through  2012. RESULTS: The majority (71%) of @entity1 received a single lung transplant. The median survival time after LTx for all @entity1030 @entity1 was 9 years (95% confidence interval [CI]: 8 to 10). Non- @entity8693 recipients had a shorter survival time than @entity8693 recipients, 6 years (95% CI: 5.0 to 8.8) versus 12 years (95% CI: 9.6 to 13.5, p  = 0.000). Mortality was higher among non- @entity8693 recipients after adjusting for age, pack-years of smoking, body mass index, @entity26 therapy use, exercise capacity, donor age, cytomegalovirus mismatch, and transplant type (hazard ratio 1.70, 95% CI: 1.02 to 2.82). The 5-year and 10-year survival rates for the @entity8693 recipients were 75% and 59%, respectively, compared with 60% and 31% for the non- @entity8693 recipients. Early deaths were mainly due to cardio/cerebrovascular accidents and @entity295 , and late deaths to @entity4154 and @entity358 . CONCLUSIONS: Survival after LTx is significantly better for @entity1 with severe @entity8693 and end stage @entity1030 than for the @entity1 with @entity1030 related to cigarette smoking.

Survival benefit of lung transplantation for XXXX in sweden.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity295 :: ('MESH:D018805', 'Disease') :: ['sepsis'] @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen'] @entity8693 :: ('MESH:D019896', 'Disease') :: ['alpha-1-antitrypsin deficiency', 'AATD'] @entity358 :: ('MESH:D008171', 'Disease') :: ['pulmonary infections'] @entity1030 :: ('MESH:D029424', 'Disease') :: ['chronic obstructive pulmonary disease', 'COPD'] @entity4154 :: ('MESH:D001989', 'Disease') :: ['bronchiolitis obliterans syndrome']
@entity1030 :: (MESH:D029424,Disease) :: ['chronic obstructive pulmonary disease']
